Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children

Pediatric Infectious Disease Journal

Volumn 22, Issue 8, 2003, Pages 701-706

  Passwell, Justen H ^a,c   Ashkenazi, Shai ^b,c   Harlev, Efrat ^b,c   Miron, Dan ^d   Ramon, Reut ^a,c   Farzam, Nahid ^a,c   Lerner geva, Liat ^a,c   Levi, Yonit ^a,c   Chu, Chiayung ^e   Shiloach, Joseph ^f   Robbins, John B ^e   Schneerson, Rachel ^e  

^a SHEBA MEDICAL CENTER   (Israel)

^b SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d HAEMEK MEDICAL CENTER   (Israel)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Conjugate vaccines; Immunization; Shigellosis

Indexed keywords

IMMUNOGLOBULIN G; SHIGELLA VACCINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; GASTROINTESTINAL DISEASE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; PAIN; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; SHIGELLA FLEXNERI; SHIGELLA SONNEI; SHIGELLOSIS;

EID: 0041736184     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000078156.03697.a5     Document Type: Article

References (31)

1. Feig M. Epidemic Shigella gastroenteritis (bacillary dysentery) in an epidemic area: 1. Incidence, distribution at various age group levels, ethiology and transmission. Wis Med J 1951;50:755-60.
2. Ashkenazi S, Dinari G, Zevulunov A, et al. Convulsions in childhood shigellosis: clinical and laboratory features in 153 children. Am J Dis Child 1987;141:208-10.
3. Dan M, Michaeli D, Treistman J. The epidemiology of shigellosis in Israel. Ann Trop Med Parasitol 1988;82:159-62.
4. Dutta P, Bhattacharya SK, Sen D, et al. Shigellosis in children: a prospective hospital based study. Indian Pediatr 1991;29:1125-30.
5. Green MS, Block C, Cohen D, et al. Four decades of shigellosis in Israel: epidemiology of a growing public health problem. Rev Infect Dis 1991;13:248-53.
6. Ferreccio C, Prado V, Ojeda A, et al. Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile. Am J Epidemiol 1991;134:614-27.
7. Robbins JB, Chu C, Schneerson R. Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Clin Infect Dis 1992;15:346-61.
8. Shears P. Shigella infections. Ann Trop Med Parasitol 1996;90:105-14.
9. Kotloff KL, Winickoff JP, Ivanoff B, et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ 1999;77:651-66.
10. Formal SB, LaBrec E, Palmer A, et al. Protection of monkeys against experimental shigellosis with attenuated vaccines. J Bacteriol 1965;90:63-8.
11. Mel DM, Terzin AL, Vuksic L. Studies on vaccination against bacillary dysentery: 3. Effective oral immunization against Shigella flexneri 2a in a field trial. Bull World Health Organ 1965;32:647-55.
12. Levine MM, Woodward WE, Formal SB, et al. Studies with a new generation of oral attenuated Shigella vaccine: Escherichia coli bearing surface antigens of Shigella flexneri. J Infect Dis 1977;136:577-82.
13. Levine MM, Kaper JB, Black RE, et al. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev 1983;47:510-50.
14. Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 1995;171:1387-98.
15. Robbins JB, Schneerson R, Anderson P, et al. The 1996 Albert Lasker Medical Research Awards. Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b. Impact on public health and implications for other polysaccharide-based vaccines. JAMA 1996;276:1181-5.
16. Cohen D, Green MS, Block C, et al. Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population. J Infect Dis 1988;157:1068-71.
17. Passwell JH, Freier S, Shor R, et al. Shigella lipopolysaccharide antibodies in pediatric populations. Pediatr Infect Dis J 1995;14:859-65.
18. Fothergill LD, Wright J. Influenzal meningitis: relation of age of incidence to the bactericidal power of blood against the causal organism. J Immunol 1933;24:273-84.
19. Cohen D, Ashkenazi S, Green M, et al. Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers. Infect Immun 1996;64:4074-7.
20. Taylor DN, Trofa AC, Sadoff J, et al. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids. Infect Immun 1993;61:3678-87.
21. Cohen D, Ashkenazi S, Green MS, et al. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet 1997;349:155-9.
22. Passwell JH, Harlev E, Ashkenazi S, et al. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel. Infect Immun 2001;69:1351-7.
23. Ashkenazi S, Passwell JH, Harlev E, et al. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children. J Infect Dis 1999;179:1565-8.
24. Chu CY, Liu BK, Watson D, et al. Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid. Infect Immun 1991;59:4450-8.
25. Pavliakova D, Chu C, Bystricky S, et al. Treatment with succinic anhydride improves the immunogenicity of Shigella flexneri type 2a O-specific polysaccharide-protein conjugates in mice. Infect Immun 1999;67:5526-9.
26. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children: Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000;19:187-95.
27. Salisbury D. Introduction of a conjugate meningococcal type C vaccine programme in the UK. J Paediatr Child Health 2001;37:S34-6.
28. Lin FY, Ho VA, Khiem HB, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001;344:1263-9.
29. Shinefield H, Black S, Fattom A, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002;346:491-6.
30. Lindberg AA, Haeggman S, Karlsson K, et al. The humoral antibody response to Shigella dysenteriae type 1 infection, as determined by ELISA. Bull World Health Organ 1984;62:597-606.
31. Pozsgay V, Chu C, Pannell L, et al. Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1. Proc Natl Acad Sci USA 1999;96:5194-7.